newsfilter
← Latest News
GlobeNewswire·

Opiant Pharmaceuticals Announces Positive Pharmacokinetic, Safety, and Tolerability Results From a Multi-Dose Study for OPNT003, Nasal Nalmefene

SANTA MONICA, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ:OPNT) today announced positive topline results from a multi-dose pharmacokinetic ("PK") study for OPNT003, nasal nalmefene, an investigational trea